Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $36

Benzinga · 11/25/2025 15:05
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $28 to $36.